Potential effects of telbivudine and entecavir on renal function: a systematic review and meta-analysis

Table 1 Characteristics of the 6 studies included in the meta-analysis

Study	Region	Study type	Interventions	Sample size	Age^a (years)	Gender (F/M)	Follow-up period
Koklu et al. (2015) [16]	Turkey	Case control	LAM/ETV/TDF	LAM: 302	LAM: 49.21 ± 13.17	292/565	2 years
				ETV: 282	ETV: 49.86 ± 13.35
				TDF: 273	TDF: 47.74 ± 12.45
Lee et al. (2015) [19]	Korea	Cohort	LdT/ETV	LdT: 116	LdT: 53.6 ± 10.9	229/465	1.5 years
Lee et al. (2015) [19]	Korea	Cohort	LdT/ETV	ETV: 578	ETV: 54.8 ± 11.3	229/465	1.5 years
Jia et al. (2015) [15]	China	Cohort	ADV/ETV	ADV: 165	ADV: 46.2 ± 9.2	95/235	5 years
Jia et al. (2015) [15]	China	Cohort	ADV/ETV	ETV: 165	ETV: 48.6 ± 8.7	95/235	5 years
Liang et al. (2014) [20]	Taiwan	Cohort	LdT/ETV	LdT: 34	LdT: 46.68 ± 1.87	10/44	1 year
Liang et al. (2014) [20]	Taiwan	Cohort	LdT/ETV	ETV: 20	ETV: 44.45 ± 1.95	10/44	1 year
Yan & Han (2012) [21]	China	RCT	LdT/ETV/ADV	LdT: 50	LdT: 37.3 (22-59)	36/79	1 years
				ETV: 35	ETV: 43.0 (21-64)
				ADV: 30	ADV: 39.4 (25-62)
Gane et al. (2013) [9]	Worldwide	RCT	LdT/LAM	LdT: 680	N/A	N/A	2 years
Gane et al. (2013) [9]	Worldwide	RCT	LdT/LAM	LAM: 687	N/A	N/A	2 years

^aAge expressed as mean ± SD or median (range)
ADV adefovir, ETV entecavir, LAM lamivudine, LdT telbivudine, N/A not applicable, RCT randomized controlled trial, TDF tenofovir

ISSN: 1743-422X